about
Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction.Cumulative incidence and risk factors for the development of hepatocellular carcinoma in patients with chronic hepatitis B who achieved sustained disappearance of viremia by nucleos(t)ide analogue treatment.Occurrence of late relapse of hepatitis C virus confirmed by molecular analysis after sustained virologic response to interferon-ribavirin-based therapy.A comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b.Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.Low skeletal muscle mass predicts early mortality in cirrhotic patients with acute variceal bleeding.Substitutions in interferon sensitivity-determining region and hepatocarcinogenesis after hepatitis C virus eradicationImpact of myosteatosis on skeletal muscle volume loss in patients with chronic liver diseaseUtility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patientsComplete response by vitamin K2 analog monotherapy in sorafenib-failure advanced hepatocellular carcinoma: A case reportLate relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapyLiver stiffness measurement predicts hepatocellular carcinoma development in patients treated with direct-acting antiviralsHepatitis B virus-related hepatocellular carcinoma in young adults: Efficacy of nationwide selective vaccinationThe Prevalence of Mixed Hepatitis C Virus Genotype Infection and Its Effect on the Response to Direct-Acting Antivirals TherapyRapid increase of platelet counts during antiviral therapy in patients with hepatitis C virus infection
P50
Q31151179-4171462D-F965-4878-8341-CAF9462D9CA8Q38596871-42C99CEA-A830-40F0-A1DF-C973A19D2CCEQ40148468-4CE01CC9-65FC-47D2-A732-429ADDAF897CQ40228836-11B60BB1-BAA8-463C-AEF1-34B10EF3990FQ40484172-D724508F-8A01-4067-9866-A598D4FBB130Q48595655-11EF67DD-4AF4-4733-9DF3-FCDC77B6274AQ58378569-FF08431A-14AB-480E-9170-A0E81A839643Q58378572-8C98DE71-7D3F-40F2-9448-A1BBD66A2778Q58378575-93251626-03EC-405E-8FFF-3AFFFFA71455Q58378580-9E44B403-25D0-4AA0-B8D7-B8484A6C9EBEQ58378585-2C4A3DE8-915B-4F46-A076-63BCB22B59FDQ58378595-E6781ABE-BE49-48D0-BCBD-E01CB47671FFQ90953500-39B810A6-8246-4C6F-AB02-65DAAD6327BCQ92812651-C037FC6C-E0D9-4345-BFA9-443554586C7BQ93180936-83CE63FB-08F9-4798-A184-3C8DA5F05D65
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-7919-6071
@en
name
Kazuhiko Hayashi
@ast
Kazuhiko Hayashi
@en
Kazuhiko Hayashi
@es
Kazuhiko Hayashi
@nl
type
label
Kazuhiko Hayashi
@ast
Kazuhiko Hayashi
@en
Kazuhiko Hayashi
@es
Kazuhiko Hayashi
@nl
prefLabel
Kazuhiko Hayashi
@ast
Kazuhiko Hayashi
@en
Kazuhiko Hayashi
@es
Kazuhiko Hayashi
@nl
P1053
I-7382-2014
P106
P31
P3829
P496
0000-0002-7919-6071